About the Speakers:
Tan Meng How, Associate Professor, School of Chemical and Biomedical Engineering, NTU
Meng How Tan is a tenured associate professor in the School of Chemical and Biomedical Engineering at Nanyang Technological University (NTU). He received his bachelor’s degrees in mechanical engineering and economics from University of California Berkeley, his master’s degrees in aeronautics and biomedical engineering from California Institute of Technology and NTU respectively, and his PhD in developmental biology from Stanford University. After postdoctoral training in Stanford, he returned to Singapore to set up his independent laboratory, focusing on the basic biology and translational applications of DNA and RNA editing. To date, he has published corresponding authored papers in top academic journals, including Nature, Nature Chemical Biology, and Nature Communications. He received the Outstanding Young Principal Investigator Award from AIChE-SLS in 2019 and was named an EMBO Global Investigator in 2020.
Liew Ee Bin, Group Executive Director, Access-2-Healthcare
Ee Bin Liew is the Group Executive Director of Access-2-Healthcare, a global consulting company with a team of more than 30 across 11 countries. The company helps medical technology companies around the world execute market entry activities such as strategic go-to-market strategies, design and development support, quality systems establishment, regulatory strategy and affairs execution, and business due diligence. Ee Bin has more than 20 years’ experience working with large multi-national companies in the medical device industry and is in the forefront of key Standards and Regulations development in the medical device industry, working directly in the ISO TC210 as part of the drafting committee for key standards in the medical device industry, and is alsoone of the Technical Committee co-chair in the Asian Harmonization Working Party (AHWP).
Ee Bin Liew | LinkedIn
Zhou Lihan, Co-founder and CEO, MiRXES Pte Ltd
Dr Lihan Zhou co-founded and serves as the CEO of MiRXES, a Singapore headquartered biotechnology company with operations in USA, China and Japan. In response to the escalating COVID-19 pandemic, MiRXES contributed its R&D and manufacturing capabilities to assist Singapore government agencies to manufacture and supply the Fortitude test, Singapore’s first approved COVID-19 RT-PCR Test. The Fortitude test has since become one of the most widely used tests globally, with deployment in more than 45 countries to date. Prior to founding MiRXES, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR, where he co-developed a novel microRNA qPCR assay platform and an integrated workflow for microRNA biomarker and therapeutic target discovery.
Lihan has a PhD in Biochemistry from the National University of Singapore. He was trained as a molecular neurobiologist with a broad trainings in other domains including qPCR technology, gene delivery, tumor targeting nanoparticles and nanostructure enhanced clinical analyte detection. Lihan has authored and co-authored more than 20 peer-reviewed publications and multiple patent applications. In 2015, Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35. MIRXES has been recognized by a number of Singapore and overseas awards including Singapore’s Most Promising Start-up in 2016 and Singapore’s Fastest Growing Companies in 2020.